Complete pathological and serological response to immunotherapy in a patient with MMR-deficient early rectal cancer
Authors:
- 1 June 2021
- journal article
- letter
- Published by Elsevier in Annals of Oncology
- Vol. 32 (6) , 805-806
Abstract
No abstract availableFunding Information
- Novo Nordisk AS
- Danish Cancer Society
This publication has 5 references indexed in Scilit:
- Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry studyThe Lancet Oncology, 2021
- Recent advances in (chemo-)radiation therapy for rectal cancer: a comprehensive reviewRadiation Oncology, 2020
- Neoadjuvant Immunotherapy–Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case SeriesJournal of the National Comprehensive Cancer Network, 2020
- Enhanced Performance of DNA Methylation Markers by Simultaneous Measurement of Sense and Antisense DNA Strands after Cytosine ConversionClinical Chemistry, 2020
- Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancersNature Medicine, 2020